Back to the atlasDownload source notes

October 2, 2026 — scheduled research update

Home · Latest · Milestones

Focused review of all 28 active topics, with overlap from the prior successful checks (September 5/6 onward) and emphasis on September 29–October 2. Source dates remain explicit; older recovered material is not labeled new October research. Every broad-topic check remains partial. Successful-check timestamps are preserved, and the gaps below are retained for the next run. No new informal claim was promoted to established evidence.

Findings

Coverage by topic

Whole-body MRI

Coverage: partial. Newly recorded items: 0.

Searches: Whole-body MRI screening outcomes September October 2026 HERCULES; NCT06212479 current registry; whole body MRI screening Reddit September 2026.

Gaps: HERCULES registry unchanged since April 30 2025: recruiting, planned 100000, estimated January 2034 primary/January 2037 final, no results. No new large prospective screening outcomes identified in focused search. October Clinical Imaging commentary located; lung-cancer staging paper excluded as not average-risk screening. Full downstream-harm/outcome literature and Lacy podcast review remain incomplete.

Informal sources: No additional attributable signal selected in this focused search; Reddit mostly older commercial-scan experiences with newer comments. Existing September 28 podcast claim not fully reassessed.

Sources checked:

Galleri and organ-specific cancer screening

Coverage: partial. Newly recorded items: 0.

Searches: Galleri FDA approval September October 2026 advisory panel; colorectal stool blood screening September 2026 SDC2; Galleri FDA approval Reddit September 2026.

Gaps: No final FDA approval verified. September 23 nonbinding panel vote already captured and is not new approval. Full organ-specific registry census, panel transcript and newly located SDC2 papers remain unappraised.

Informal sources: Unresolved; no new corroboration; Reddit approval timing remains speculation; no official action date identified. Original source

Sources checked:

Coverage: partial. Newly recorded items: 2.

Searches: EASD September 29–October 2 EloraTZP TRIUMPH-2 new results; Lilly September30 analyst slides and NCT06603571 original registry; Eloralintide Reddit September30 combination results.

Gaps: Selective conference and registry review, not a full worldwide incretin, insulin, safety or access census. Full TRIUMPH-2 paper and supplements were not retrieved; indexed primary abstract and sponsor tables were appraised. No curve digitization completed; T2D weight results must stay separate from the current non-diabetic weight-map population.

Informal sources: September30 Reddit EloraTZP discussion repeats released data; a 29%-at-31-week claim was not corroborated and was not added as trial evidence. Original thread: https://www.reddit.com/r/mounjarouk/comments/1wu5875/eloralintide_tirzepatide_results_are_out_even/ . Full conference Q&A audio not appraised.

Sources checked:

Muscle building and preservation

Coverage: partial. Newly recorded items: 0.

Searches: BELIEVE EASD September30 bimagrumab withdrawal full slides; enobosarm Veru September2026 PLATEAU SRK439 deramiocel October3.

Gaps: BELIEVE abstract was already reported; full post-presentation arm denominators, intervals and safety tables not recovered. The elapsed presentation date does not prove new results. Sarcopenia and disease-specific registry census incomplete. Deramiocel October3 presentation remains future; no results inferred.

Informal sources: Bimagrumab/Veru Reddit discovery yielded no additional attributable development claim selected. Earlier Cantor Phase3-direction rumor remains unresolved; original recording not reviewed.

Sources checked:

Longevity and healthspan trials

Coverage: partial. Newly recorded items: 0.

Searches: human longevity metformin rapamycin senolytics September2026 October 2026; MAVRIC NCT07520110 original registry; Reddit longevity trial September2026.

Gaps: MAVRIC remains NOT_YET_RECRUITING in September8 record despite elapsed September28 estimated start. No actual initiation verified. Full refresh of all senolytic/mTOR registries, TAME funding, RESTOR and original podcast recordings incomplete. Search results mainly reviews/preclinical stories, not a completed new lifespan trial.

Informal sources: September4 metformin Reddit item repeats a review, not new TAME results. Existing PEARL 24-month-paper claim not confirmed; no repeat alert.

Sources checked:

Localized fat removal and cellulite

Coverage: partial. Newly recorded items: 1.

Searches: CBL514 EASD2026 human visceral fat analysis September30 October2; SUPREME01 AYP101 tesamorelin original registries; CBL514 tesamorelin RZL012 cellulite new human results informal signals.

Gaps: Conference report is an exploratory pooled MRI subgroup, not a full peer-reviewed VAT trial report; selection, missingness and intervals need original tables. No independently verified SUPREME02 recruitment milestone, new RZL012 readout or complete cellulite-comparison census. Tesamorelin and AYP101 API refreshed; no new result selected.

Informal sources: Sponsor LinkedIn confirms the EASD talk occurred; separate gray-market/self-experimentation claims excluded. No new attributable informal timing or efficacy claim selected.

Sources checked:

Broad cardiovascular prevention, lipids and screening

Coverage: partial. Newly recorded items: 2.

Searches: VERVE102 October 2026 phase2 HEART3 NCT07839936; new lipid lowering trial September30 October1 DR10624; Reddit cholesterol CRISPR trial September2026.

Gaps: No complete Lp(a), gene-editing, ApoB or screening registry refresh. COMPETE SWITCH CV original HR orientation and event counts remain unresolved; not inserted into randomized plots.

Informal sources: CRISPR Reddit headlines repeat earlier CTX310 findings, not independent new results. No original new VERVE data leak or recording appraised.

Sources checked:

Alzheimer's screening and therapies

Coverage: partial. Newly recorded items: 1.

Searches: Alzheimer trial results September 29 October 1 2026; Alzheimer blood test September 2026; ClinicalTrials.gov SPINOZA obicetrapib NCT07794670; ALN-5288 NCT07214727; ceperognastat PROSPECT-ALZ JAMA September 22 2026 July publication date; site:reddit.com Alzheimer trial September 2026; Alzheimer prevention obicetrapib informal discussion.

Gaps: Full refresh of antibody safety labels, blood-test regulatory inventory, ALZ101 and matched PrevenTRON registries was not completed. Original Attia/Davidson episode was not reopened; registry now verifies recruiting but not preventive benefit.

Informal sources: Obicetrapib dementia prevention / Attia-Davidson signal; No efficacy confirmation. SPINOZA recruitment is officially registry-listed; do not equate biomarker study with proven prevention. https://www.reddit.com/r/Nutraceuticalscience/comments/1wqjj05/alzheimers_is_no_longer_an_untreatable_disease/; September 26 reposted consensus/personal discussion; no distinct new trial signal.

Other observations: ALN-5288 registry remains recruiting, phase 1, 50 planned; actual October 15 2025 start, March 6 2030 estimated primary. A September 14 record update is not a new trial launch. Ceperognastat PROSPECT-ALZ JAMA issue dated September 22 is NOT a fresh result: first published online July 13 2026. Useful missed baseline safety context only; high-dose clinical decline despite favorable biomarker changes. Do not label as October news. Prior Sept29 XanaMIA, RADIANT and TRONTIER reports deduplicated.

Sources checked:

Coverage: partial. Newly recorded items: 0.

Searches: psilocybin LSD DMT clinical trial September 30 October 1 2026; site:fda.gov psychedelic September 2026 hearing transcript; COMP360 NDA September 2026; GH001 phase 3; HLP003 Psych Congress September 2026; Resilient MDMA NDA resubmitted FDA September 2026 Reddit; site:reddit.com/r/shroomstocks September 28 2026.

Gaps: September 14 FDA hearing full recording/transcript not comprehensively appraised. HLP003 Psych Congress posters 121–124 not obtained; September 21 sponsor release gives analyses but no sufficiently detailed new quantitative table. All worldwide psychedelic trial registries, safety updates and podcast transcripts not exhaustively refreshed.

Informal sources: Resilient/Lykos MDMA application reportedly resubmitted; https://www.reddit.com/r/PharmAla_MDMA/comments/1wtlput/introducing_the_pharmala_pulse_a_brief_roundup_of/; September 29 secondhand roundup repeats existing claim, not independent corroboration. No FDA acceptance verified; retain existing unresolved rumor status, no repeated alert. https://www.reddit.com/r/shroomstocks/comments/1wse09j/rshroomstocks_weekly_discussion_thread_september/; September 28 thread with September 30 comments contained approval/NDA expectations, not independently sourced new inside information.

Other observations: FDA public-hearing comments remain due October 5 2026 at 11:59 p.m. Eastern; no changed approval policy inferred. COMP005/DT120/Optimi/bipolar II pilot developments already in notebook; no duplicate findings added. uAspire NCT06308653 has July 23 active-not-recruiting record, 238 actual enrollment, actual January 5 2026 primary completion; no posted results. ELUMINA NCT06524830 remains stale May 11 recruiting snapshot with elapsed August estimates, despite July sponsor last-dose announcement; no completion or results assumed.

Sources checked:

Mental-health treatments, SSRIs and newer antidepressants

Coverage: partial. Newly recorded items: 2.

Searches: new antidepressant anxiety OCD PTSD bipolar addiction trial September 29 October 1 2026; ClinicalTrials.gov oral ketamine midazolam KOMET NCT07839338; ClinicalTrials.gov BAARD biotype antidepressant aripiprazole bupropion NCT07810738; site:reddit.com antidepressants clinical trial September 2026 PIPE-307 fasedienol.

Gaps: Broad OCD/PTSD/addiction/anxiety pipeline and all antidepressant safety/label changes not fully refreshed. Informal-source searches were performed, but no distinct new attributable rumor was verified; podcasts/talks not exhaustively reviewed.

Informal sources: Targeted Reddit/program searches did not produce a distinct sourced new claim suitable for alerting. This is not an exhaustive no-rumor finding.

Other observations: ASTRO, fasedienol exploratory findings after failed primary endpoint, lumateperone mania, VTA neurofeedback primary miss, PIPE-307 and KetSet already in Sep29 record; deduplicated. Keep oral ketamine entries in mental health, with cross-links to psychedelic-related approaches if useful; do not fold SSRI, ketamine and classic psychedelics into one drug class.

Sources checked:

Bone health, joint preservation and cartilage repair

Coverage: partial. Newly recorded items: 0.

Searches: lorecivivint EMA September 2026 application; TG-C ACTiVION October 2026 NCT03203330; bone cartilage osteoporosis September 2026 trials Reddit.

Gaps: Lorecivivint September EMA-filing forecast elapsed; no achievement verified in checked sponsor news. Retain as elapsed/unconfirmed, not completed or failed. ACTiVION I August 20 registry: active not recruiting, actual n535, actual primary July 10 2024, estimated final August 18 2026; no posted results. October sponsor readout forecast pending. Full Cell paper, EB613 initiation, fracture evidence and broad bone/cartilage trial census incomplete.

Informal sources: No additional attributable signal selected in this focused search; September 15 living-medicine Reddit appears to repeat existing small-study coverage; full-paper review outstanding.

Sources checked:

Sleep therapies and sleep disorders

Coverage: partial. Newly recorded items: 2.

Searches: digital insomnia therapy network meta analysis September 28 2026 s12916-026-05129-8; Orzeyful availability November 2026 DEA Federal Register; alixorexton Vibrance 3 ClinicalTrials.gov; restless legs syndrome September 2026 RLS Science Outcomes Summit TOMAC; site:reddit.com/r/Narcolepsy September 2026 new medication Japan Orzeyful.

Gaps: DEA scheduling was searched but not independently established from a final official action. RLS conference full presentations, circadian studies, all new digital products and broad sleep registries were not comprehensively appraised. September 16 venous radiofrequency ablation observational RLS paper full methods not appraised; do not promote as established treatment evidence.

Informal sources: https://www.reddit.com/r/Narcolepsy/comments/1wr7at2/new_medication_made_in_japan/; September 27 discussion repeats expected November access, with no independently verified new U.S. price or launch. https://www.reddit.com/r/Narcolepsy/comments/1whl8i0/did_anyone_here_participate_in_the_clinical/; Trial-participant anecdotes were not treated as efficacy or population safety results.

Other observations: Orzeyful official website still says expected availability by November 2026 pending DEA scheduling; no verified change. THRIVE/TOMAC paper is first online June 3 2026 despite September issue; avoid recycling as fresh September news. AD109 NCT05813275 results first posted September 11 concern already public trial findings; raw results tables not newly appraised. Brilliance phase3 trials remain recruiting in checked snapshots; no new readout established.

Sources checked:

Liver health and noninvasive assessment

Coverage: partial. Newly recorded items: 1.

Searches: MASH September30 October 2026 new trials and EASL EASD EASO guidance; EMA Wegovy September2026 CHMP MASH outcome; EASL Talk Liver to Me September30 resmetirom semaglutide.

Gaps: EU September Wegovy MASH procedure outcome still not verified; an agenda or guidance publication does not establish approval. Broader fibrosis, cirrhosis and noninvasive-test registry census incomplete. Guidance full recommendation tables not systematically appraised.

Informal sources: EASL September30 podcast page verified: Debbie Shawcross with Andreea Ciudin, Amalia Gastaldelli and Frank Tacke. Show notes discuss guidance; full audio not reviewed and no new rumor inferred. Existing CHMP-omission Reddit inference remains unconfirmed.

Sources checked:

Cancer treatment, vaccines and recurrence prevention

Coverage: partial. Newly recorded items: 1.

Searches: giredestrant evERA NEJM September 30 2026; Genentech September 2026 giredestrant FDA December 18; cancer therapy September October 2026 phase 1 first patient IDOV2.

Gaps: NEJM primary abstract retrieved via primary-source search indexing; full paper returned 403. Severe-harm/discontinuation tables and supplements not appraised. Broad oncology and vaccine registry coverage incomplete. IDOV2 first-cohort notice located but not fully appraised.

Informal sources: No new rumor selected; comprehensive informal-source review remains incomplete.

Sources checked:

Autoimmune disease and immune reset

Coverage: partial. Newly recorded items: 2.

Searches: miv-cel KYSA-8 September 24 2026 one year; fenebrutinib FDA September 29 2026 priority review; rapcabtagene zolecabtagene pause restart September 2026; C-CAR168 NCT07729826 lupus; Saurabh Mehandru Mount Sinai CAR T IBD September 2026.

Gaps: Rapcabtagene/zolecabtagene registry updates predate pauses, cannot establish restart; no original restart announcement verified. C-CAR168 September 10 registry not yet recruiting despite estimated September 30 start; planned 50, single-arm phase 2 LN, week-65 complete renal response. Actual initiation unconfirmed. Full miv-cel safety tables, fenebrutinib fatality attribution, complete immune-reset registry census and informal review incomplete.

Informal sources: Mount Sinai September 22 IBD CAR-T planning statement; Unresolved; no new corroboration; Investigator planning statement revisited; no matched newly initiated formal study. Keep original informal-statement status, no duplicate alert. Original source

Sources checked:

Non-opioid pain treatments

Coverage: partial. Newly recorded items: 1.

Searches: onzotrigine LTG321 September 2026 phase 2 phase 3; PEPTIDE pamidronate trial September 2026; Journavx VX993 Tonmya PAINweek September 2026; NCT06628908 current registry.

Gaps: NCT06628908 June 15 registry remains recruiting, May 31 2027 estimated primary/final; other DPN trial NCT07231419 not refreshed, so do not globally replace April milestone. September 3 Latigo/SEC baseline lead: LTG321 once-daily knee-OA phase 2 crossover ~120 participants Denmark, H2 2027 forecast; onzotrigine phase 3 plans. Trial IDs and claimed original NEJM paper not matched. Not selected as efficacy news. Tonix poster landing page checked, PDFs not appraised. VX993, full safety and broad registry census incomplete. PEPTIDE PMC blocked but original PubMed abstract read.

Informal sources: No additional attributable signal selected in this focused search; Off-label Journavx anecdotes not treated as trial outcomes; broader informal sweep incomplete.

Sources checked:

Kidney preservation and earlier detection

Coverage: partial. Newly recorded items: 2.

Searches: new kidney therapies September30 October 2026; ExploreCKD lorundrostat September23 primary publication; NCT06926660 vicadrostat empagliflozin latest registry.

Gaps: Lorundrostat full safety/CI table not appraised; selected primary publication details only. Complete worldwide CKD and detection registry census not completed. Sefaxersen interim magnitude, longer-term clinical outcomes, and atacicept final safety tables remain gaps.

Informal sources: Kidney forum searches mainly personal experiences and animal-kidney speculation; no new attributable formal-development rumor selected. Full audio not appraised.

Sources checked:

Hearing and vision preservation/restoration

Coverage: partial. Newly recorded items: 4.

Searches: Rincell-1 NCT07032038 October 1 2026; AC102 NCT05776459; EURETINA October 2026 PRIMA 36-month outcomes; MOGENRY BLA acceptance September 2026; Nanoscope EURETINA October 4 2026 macular degeneration MCO-010; PST-611 EURETINA October 2 2026; GAL-101 eDREAM baseline October 1; AC102 phase 3 2027 Reddit email; hearing restoration September 2026 clinical trial.

Gaps: Actual October1–2 EURETINA posters/slides and PST-611 presentation not fully appraised; no new numerical results inferred from schedules. Full DAYBREAK noninferiority confidence intervals, BRUNELLO safety detail, all ophthalmic FDA labels and acquired-loss trial inventory were not refreshed. MCO-010 macular-degeneration trial registry was not conclusively matched.

Informal sources: AC102 possible 2027 phase3 / tinnitus route; https://www.reddit.com/r/tinnitusresearch/comments/1w1vebv/audiocure_ac102_update/; Original August29 Reddit secondhand email account revisited; original email unavailable. NCT05776459 still has January16 active-not-recruiting record with elapsed February28/July31 estimates. No new results or phase3 launch confirmed; keep rumor unresolved.

Other observations: GAL-101 eDREAM October1 release describes baseline microperimetry measurement/repeatability, not treatment efficacy; no positive efficacy alert. DAYBREAK, Otarmeni access, remigromig, OCU400, Paliroden and BEST1 were already reported September29 and deduplicated. Inherited RP and Rincell neural hearing loss remain distinct from common acquired AMD/hearing loss.

Sources checked:

Hair loss, restoration and graying

Coverage: partial. Newly recorded items: 2.

Searches: bempikibart SIGNAL-AA EADV September 30 2026 off drug; hair loss September 2026 trial PP405 ABS201 clascoterone BQ002; site.investor.lilly.com 2026 Olumiant adolescents alopecia FDA September; site.accessdata.fda.gov Olumiant alopecia adolescents 2026 12 years; site:reddit.com tressless PP405 clascoterone September 2026 BQ002.

Gaps: Not a comprehensive global trial/registry or regulator refresh. UP-AA EADV week-52 abstract not appraised; conference schedules are not actual results. No full confidence intervals/participant disposition for bempikibart presentation recovered. PP405 record remained NOT_YET_RECRUITING at Sep18 update; estimated September start has elapsed without verified commencement. ABS201 remained recruiting; BioCopper hair-graying trial remained not yet recruiting with November estimated start. Other saved pipeline entrants need fuller refresh.

Informal sources: Clascoterone U.S. launch speculation; Still unconfirmed; https://www.reddit.com/r/tressless/comments/1v6rr61/clascoterone_wont_be_available_until_q4_2027_at/; Sponsor H1 2026 release still projects Q1 2027 U.S. filing and Q2 2027 European filing, not a launch date. BQ-002 2027 phase 1 rumor; Still unconfirmed; https://www.reddit.com/r/greyhairreversal/comments/1t0k55l/bioq_is_developing_an_injectable_drug_bq002/; BioQ pipeline verifies a candidate; no matching registry or confirmed 2027 trial start located. PP405 recruitment rumor; Still unconfirmed; https://www.reddit.com/r/tressless/comments/1wh8oo6/pelage_pharmaceuticals_phase_3_trials_for_pp405/; Previously logged Sept15/16 post and Sept25 comment about an August email remain secondhand. Sep18 registry status not yet recruiting; its elapsed estimate does not prove recruitment did not start.

Sources checked:

Skin aging, laxity and regeneration

Coverage: partial. Newly recorded items: 2.

Searches: skin aging rejuvenation September October 2026 randomized trial microneedling polynucleotide; KB304 biosome clinical trial September 2026; skin aging clinical trial September 2026 Reddit podcast rapalog.

Gaps: KB304 registry remains active not recruiting with stale 2025 estimated completion; no fresh results verified. Regulator/device clearance and global comparative procedure coverage incomplete. Polynucleotide full text and detailed harms remain unreviewed.

Informal sources: Informal lead; not clinical evidence; https://podcasts.apple.com/us/podcast/ozempic-face-why-weight-loss-can-make-you-look-older/id1585563694?i=1000792178470; Sept29 Robert Lufkin/Kay Durairaj episode description mentions topical rapalog and facial aging. Full audio/transcript and any linked formal human trial were not verified; do not repeat mechanistic claims as outcomes.

Sources checked:

Scar prevention, treatment and stretch marks

Coverage: partial. Newly recorded items: 1.

Searches: SNT-9465 SNT-6302 October 1 2026 scars Syntara; verteporfin SCARFREE siSPARC September October 2026 trial; site:reddit.com verteporfin trial September 2026.

Gaps: Matching Syntara registry IDs remain unverified. Geneva verteporfin and SCARFREE still not yet recruiting in stale records with elapsed start/completion estimates; do not presume progress. siSPARC status UNKNOWN with last update June2024. Stretch-mark-specific trials and full global scar program refresh incomplete.

Informal sources: No additional qualifying signal selected; https://www.reddit.com/r/verteporfin/comments/1vypnsk/verteporfin_status_upcoming_trials_and/; Old Aug26 thread and September comments are secondhand/off-label procedure discussion, not formal trial results or verified regulatory clearance.

Sources checked:

Facial volume restoration and contour

Coverage: partial. Newly recorded items: 0.

Searches: facial volume filler fat graft randomized trial September October 2026; post weight loss facial volume GLP1 September 2026 trial; site:reddit.com facial contours filler September 2026 Adipeau; Ozempic Face Kay Durairaj September 29 2026 podcast.

Gaps: Focused search did not establish a new material primary result; this is not a full no-news check. Macro-fat registry NCT07805889 remains recruiting, target400, with Dec10 2026 primary and Mar1 2027 final estimates; no results. Full device/regulator/soft-tissue filler inventory and conference abstracts not appraised.

Informal sources: Promotional lead; not clinical evidence; https://www.reddit.com/r/u_Adipeau/comments/1wubdvg/restoring_facial_contours_without_filler_where/; Search indexed Sept30 brand promotion of facial-contour claims; full original could not be fetched. No new controlled human outcome verified. Episode description only; https://www.buzzsprout.com/1848150/episodes/19344405-ozempic-face-why-weight-loss-can-make-you-look-older-kay-durairaj-md?t=0; Episode301 Sept29 with Robert Lufkin and Kay Durairaj indexed; only description/snippets assessed. No exact timestamp or full transcript read; do not present GLP1-specific facial-aging or rapalog claims as established.

Sources checked:

Pigmentation and uneven skin tone

Coverage: partial. Newly recorded items: 1.

Searches: upadacitinib Viti-Up EADV October1 2026 76 weeks; povorcitinib ruxolitinib EADV September30 2026 vitiligo P2467 P1780; vitiligo melasma new clinical trial September 2026 KT939 DelVito; melasma podcast September2026.

Gaps: Actual Incyte EADV posters P2467/P1780/P2463 were not recovered; do not convert announced presentations into appraised results. KT939 original protocol/filing remains unresolved; broad melasma/post-inflammatory pigmentation and STOP-V registry refresh incomplete.

Informal sources: No additional qualifying signal selected; https://podcasts.apple.com/ca/podcast/episode-106-treating-melasma-for-the-long-term-the/id1398257291?i=1000788746788; Sept9 melasma/long-term-treatment discussion found; no fresh formal-program claim or trial update verified. Full transcript not appraised.

Sources checked:

Acne and rosacea

Coverage: partial. Newly recorded items: 1.

Searches: denifanstat acne September30 2026 52weeks AURORA; acne rosacea EADV September October 2026 new trial; site:reddit.com acne denifanstat September2026; SP0268 rosacea erythema trial September2026.

Gaps: AURORA matching registry remains unresolved. Registry refresh confirms SP0268 recruiting800 with Nov2028 completion estimate and rosacea redness NCT07521462 recruiting50 with June2027 estimate; no results. Comprehensive antibiotic/biologic/device comparisons and safety-regulator sweep incomplete.

Informal sources: No additional unconfirmed claim selected; https://lifescievents.com/event/sdj928tn/; Sept30 Julie Harper sponsor KOL event listing assessed; Q&A/transcript not appraised. Targeted Reddit search did not yield a noteworthy new program rumor.

Sources checked:

Dental alignment, regeneration and repair

Coverage: partial. Newly recorded items: 1.

Searches: direct printed aligners randomized trial September24 2026 NCT06685029; dental alignment regeneration September October 2026 clinical trial TRG035; site:reddit.com dental tooth regrowth September2026.

Gaps: Full orthodontic paper could not be retrieved. NCT07496892 still not yet recruiting in March record although September completion estimates have elapsed; no presumed completion. Toregem phaseIIa first dosing and full regeneration/retention/root-safety inventory remain unresolved.

Informal sources: Repost of an older forecast; no new development established; https://www.reddit.com/r/Biohackers/comments/1wq1adh/910_dentists_probably_wont_recommend_this/; Sept25 repost repeats possible2030 tooth-regrowth availability; no new controlled human results. Toregem news page did not verify first phaseIIa dosing.

Sources checked:

Allergy and airway disease

Coverage: partial. Newly recorded items: 2.

Searches: rademikibart Seabreeze STAT COPD September 30 2026 results; DBV VIASKIN Peanut BLA September 29 2026; NCT06940154 NCT05741476 current registry; rademikibart VIASKIN Reddit September 2026.

Gaps: COPD release omits absolute event counts, confidence intervals, quantitative harms and key secondary week-1 FEV1; no registry result tables. VITESSE registry January update predates actual n654. Submission does not equal FDA acceptance or granted Priority Review. Broad COPD/asthma/sinus/allergy discovery and informal transcript coverage incomplete.

Informal sources: No additional attributable signal selected in this focused search; No independent noteworthy rumor selected; two sponsor forecast milestones now formally reported.

Sources checked:

Infectious-disease prevention and treatment

Coverage: partial. Newly recorded items: 2.

Searches: VYD2311 LIBERTY DECLARATION September 29 2026 topline; new antibiotics phage human trials September October 2026; REPhRAME recurrent urinary infection September 2026; VYD2311 Reddit September 2026 efficacy; Mayo phage UTI trial Reddit September 2026.

Gaps: Broad antibiotic-class, resistance, vaccine, antiviral and long-acting prevention census incomplete. LIBERTY/DECLARATION June registry updates lag September sponsor data; no efficacy inference from status. REPhRAME protocol, registry, enrollment target and actual initiation not verified.

Informal sources: VYD2311 efficacy speculation; Speculation, not a trial result; Reddit repeats 70–90% efficacy expectation. Original sponsor describes target, not observed efficacy; no separate confirmed finding. Original source; Anonymous Mayo UTI-phage comment; Unconfirmed secondhand lead; not selected for an alert; Anonymous comments refer to future Gina Suh/Mayo UTI phage trial. Original announcement, trial match and precise comment permalink unverified; possibly recycled old program. Original source

Sources checked:

Genetic screening and risk prediction

Coverage: partial. Newly recorded items: 0.

Searches: genomic newborn screening polygenic risk clinical utility pharmacogenomics September 29 October 1 2026; genetic embryo selection Nucleus Vitruvian 14 IQ points September 2026 original source; ClinicalTrials.gov NCT07841769 NCT07802496 October 2026 recruitment; site:reddit.com genetics Generation Study September 2026 results embryo selection.

Gaps: Full prospective clinical-utility and cascade-testing inventory, pharmacogenomic trials and professional guidance were not exhaustively refreshed. Nucleus whitepaper/full ancestry calibration and original social post behind the 14-point claim were not obtained. BEACONS-NBS condition-selection preprint identified but full methods not appraised; no prospective benefit claim made.

Informal sources: Nucleus/Vitruvian 14-IQ-point embryo-selection claim; https://www.reddit.com/r/singularity/comments/1wrq633/introducing_vitruvian_a_genetic_optimization/; Still secondhand and unconfirmed. Official Labs page rechecked October2 still describes approximately 10.8 points as modeled highest-to-lowest spread among five embryos; this is not average gain over random selection, not an observed offspring result and does not corroborate the separate 14-point framing. No new rumor alert. https://www.reddit.com/r/BeyondTheBumpUK/comments/1wpsxs1/the_generation_study_we_heard_back_and_its_not/; September25 individual newborn-screening result discussion is a personal account, not new cohort clinical-utility evidence.

Other observations: Nucleus observational NCT07841769 remains not-yet-recruiting with unchanged September25 record; October1 estimated start is now elapsed and unverified. Do not assume enrollment commenced. PATHST1D NCT07802496 remains not-yet-recruiting in September8 record; October15 start and October2029 completion remain estimates. September25 policy interview and September30 GenoWell individual case are not prospective trial results; no new efficacy finding promoted.

Sources checked:

Website publication

Website publication is tracked separately in state.json; this log records the research and source checks.